Literature DB >> 20400979

Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation.

D Lane1, N Goncharenko-Khaider, C Rancourt, A Piché.   

Abstract

Interactions between ovarian cancer cells and the surrounding tumor microenvironment are not well characterized. We have earlier shown that ovarian cancer ascites induces Akt activation and protect tumor cells from TRAIL-induced apoptosis. Here, we investigated the mechanism by which ascites activates Akt. The ability of ovarian cancer ascites to activate Akt and inhibit TRAIL-induced cell death and caspase activity was decreased by heat inactivation, but was retained in ascites fractions >5 kDa. The survival promoting activity of ascites was not affected by inhibitors of growth factor receptor including epidermal growth factor receptor (EGFR), VEGFR, FGFR, Her2/neu, and IGF-R1. However, this activity was inhibited by an alphavbeta5 integrin-blocking antibody, but not by blocking antibodies against alphavbeta3, beta1, or beta3 integrins. alphavbeta5 integrin-blocking antibodies also inhibited ascites-induced Akt phosphorylation and c-FLIPs up-regulation. Ovarian cancer ascites induced a rapid phosphorylation of focal adhesion kinase (FAK), which closely correlated with the phosphorylation of Akt overtime. FAK phosphorylation was strongly inhibited by alphavbeta5 integrin-blocking antibodies. Depletion of FAK content by RNA interference was also associated with inhibition of ascites-mediated Akt activation and survival. These results suggest that ovarian cancer ascites induces FAK and Akt activation in an alphavbeta5 integrin-dependent pathway, which confers protection from TRAIL-induced cell death and caspase activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400979     DOI: 10.1038/onc.2010.107

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.

Authors:  Rohann J M Correa; Monica Komar; Jessica G K Tong; Milani Sivapragasam; Masmudur M Rahman; Grant McFadden; Gabriel E Dimattia; Trevor G Shepherd
Journal:  Gynecol Oncol       Date:  2012-02-01       Impact factor: 5.482

2.  Vitronectin inhibits neutrophil apoptosis through activation of integrin-associated signaling pathways.

Authors:  Hong-Beom Bae; Jaroslaw W Zmijewski; Jessy S Deshane; Degui Zhi; Lawrence C Thompson; Cynthia B Peterson; David D Chaplin; Edward Abraham
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

3.  Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Authors:  Isabelle Matte; Denis Lane; Dimcho Bachvarov; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2014-04-24       Impact factor: 4.430

4.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 5.  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.

Authors:  Duangmani Thanapprapasr; Wei Hu; Anil K Sood; Robert L Coleman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment.

Authors:  Ke Ma; Wan Fu; Ming Tang; Chaohua Zhang; Tianyun Hou; Ran Li; Xiaopeng Lu; Yanan Wang; Jingyi Zhou; Xue Li; Luyao Zhang; Lina Wang; Ying Zhao; Wei-Guo Zhu
Journal:  Autophagy       Date:  2017-01-19       Impact factor: 16.016

7.  Integrin α5 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells.

Authors:  Sicong Hou; Weiguo Jin; Weiming Xiao; Bin Deng; Dacheng Wu; Jiehua Zhi; Keyan Wu; Xiaowei Cao; Shuai Chen; Yanbing Ding; Hongcan Shi
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

8.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

Review 9.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

Review 10.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.